Stock 6617 GONGWIN BIOPHARM HOLDINGS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Gongwin Biopharm Holdings Co., Ltd.

Equities

6617

KYG409471060

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
153 TWD +3.73% Intraday chart for Gongwin Biopharm Holdings Co., Ltd. +19.07% -17.07%
14/05 Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
08/05 Gongwin Biopharm Co., Ltd. announced that it expects to receive TWD 300 million in funding from Gongwin Biopharm Holdings Co., Ltd. CI

Business Summary

Gongwin Biopharm Holdings Co Ltd is a company engaged in the research and development of anti-cancer medicine, especially focuses on the precise treatment to tumors. The Company’s headquarter is located in Taiwan and it created a cross-regional platform composed of Taiwan, China Mainland and the United States. The new PTS drug researched and developed by the Company is a new drug product for cancer treatment combined with minimally invasive interventional therapy technology, including PTS100 for the treatment of liver cancer, PTS302 for the treatment of lung cancer, PTS-02 for the treatment of rare diseases, PTS500 for the treatment of malignant pleural effusion and pets medication GWA101 and others.

Sales per Business

TWD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
1 100.0 % 19 100.0 % +1,554.86%

Sales per region

TWD in Million2022Weight2023Weight Delta
Taiwan
100.0 %
1 100.0 % 19 100.0 % +1,554.86%

Managers

Managers TitleAgeSince
Mao Yuan Lin CEO
 Chief Executive Officer - 01/14/01
Wei Nan Hu DFI
 Director of Finance/CFO - 01/17/01

Members of the board

Members of the board TitleAgeSince
Lieh Lin Chan BRD
 Director/Board Member - 04/18/04
Chih Tung Yang BRD
 Director/Board Member - 28/16/28
Lester John Wu CHM
 Chairman - 28/16/28
Mao Yuan Lin CEO
 Chief Executive Officer - 01/14/01
Shao Wen Kuo BRD
 Director/Board Member - 28/16/28
Chia Shun Shi FOU
 Founder - 27/14/27
Ssu Hsin Hsiao IRO
 Public Communications Contact - 01/14/01
Wei Ta Cheng BRD
 Director/Board Member - 28/16/28
Chi Hsiu Liu BRD
 Director/Board Member - 04/18/04

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 113,337,000 113,336,100 ( 100.00 %) 0 100.00 %

Shareholders

NameEquities%Valuation
Yi Chuang Wu
25.16 %
28,509,946 25.16 % 161 M NT$
Lester John Wu
12.99 %
14,720,000 12.99 % 83 M NT$
Chia Shun Shi
5.934 %
6,725,000 5.934 % 38 M NT$
Mao Yuan Lin
3.891 %
4,409,698 3.891 % 25 M NT$
Shao Wen Kuo
0.8277 %
938,100 0.8277 % 5 M NT$
Chi Hsiu Liu
0.5306 %
601,315 0.5306 % 3 M NT$
Lieh Lin Chan
0.1456 %
165,000 0.1456 % 932 116 NT$
Chuan Ching Yang
0.1397 %
158,314 0.1397 % 894 346 NT$

Company contact information

Gongwin Biopharm Holdings Co., Ltd.

3/F, No. 80, Section 1 Jianguo North Road

, Taipei

+

http://gongwinbiopharm.com
address Gongwin Biopharm Holdings Co., Ltd.(6617)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GONGWIN BIOPHARM HOLDINGS CO., LTD. Stock Gongwin Biopharm Holdings Co., Ltd.
-17.07% 532M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.49% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.73% 115B
ARGENX SE Stock argenx SE
+20.84% 26.64B
BIONTECH SE Stock BioNTech SE
-21.81% 19.91B
GENMAB A/S Stock Genmab A/S
-16.84% 16.32B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.52B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.81% 15.49B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+62.72% 14.83B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.09% 13.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6617 Stock
  4. Company Gongwin Biopharm Holdings Co., Ltd.